- All the subjects participating in InMed Pharmaceuticals' (OTCQX:IMLFF) 755-101-HV Phase 1 trial have completed treatment and clinical evaluation.
- More news on: InMed Pharmaceuticals Inc., Healthcare stocks news, Read more ...
home / stock / imlff / imlff news
Market Wire News is a media platform, the information on this page was provided by SeekingAlpha via Quote Media. Read our full disclaimer.
When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
News, Short Squeeze, Breakout and More Instantly...
InMed Pharmaceuticals Inc. Company Name:
IMLFF Stock Symbol:
Market:
InMed Announces Closing of US$4.5 Million Private Placement PR Newswire VANCOUVER, BC , Feb. 16 , 2021 /PRNewswire/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (Nasdaq: INM) (TSX: IN), a clinical-stage pharmaceutical company developing medicat...
InMed Pharmaceuticals Reports Second Quarter Fiscal 2021 Financial Results Canada NewsWire VANCOUVER, BC , Feb. 11, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company develo...
InMed Pharmaceuticals to Report Second Quarter Fiscal 2021 Financial Results Canada NewsWire VANCOUVER, BC , Feb. 5, 2021 /CNW/ - InMed Pharmaceuticals Inc. ("InMed" or the "Company") (NASDAQ: INM) (TSX: IN), a clinical-stage pharmaceutical company developing...